Timing of Oral Calcitonin for Osteoporosis Treatment
Author Information
Author(s): Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C
Primary Institution: Nordic Bioscience A/S
Hypothesis
Does the timing of oral calcitonin administration affect its efficacy in suppressing bone resorption in postmenopausal women?
Conclusion
Orally administered 0.8 mg of salmon calcitonin is effective in suppressing serum CTX regardless of the time of dosing, with pre-dinner dosing showing the best results.
Supporting Evidence
- Morning and pre-dinner dosing led to comparable concentration of sCT of 45 pg/ml.
- Pre-dinner dosing resulted in optimum efficacy response corresponding to an overall suppression of bone resorption by 25%.
- The maximum difference from placebo was observed 1 to 3 hours post-dose with a 40 to 50% suppression after morning dose.
Takeaway
Taking a medicine called calcitonin at different times of the day can change how well it works to help bones, and taking it before dinner seems to be the best time.
Methodology
The study was a randomized, double-blind, double-dummy, placebo-controlled, phase I study assessing the pharmacokinetic and pharmacodynamic profiles of oral salmon calcitonin in healthy postmenopausal women.
Potential Biases
No randomization of subjects may introduce bias in the comparisons between dosing times.
Limitations
Comparisons between the three dosing times may be affected by bias due to lack of randomization.
Participant Demographics
Healthy postmenopausal women aged 40–70 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
69% to 120%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website